SCHEMBL1269864

SCHEMBL1269864

N=C(N)NS(=O)(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 4/20 0.49
FLT4 P35916 4/20 0.49
KDR P35968 4/20 0.49
ITGA1 P56199 4/20 0.46
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
ALOX12 P18054 1/20 0.43
KMT2A Q03164 1/20 0.43
NLRP1 Q9C000 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
EDNRA P25101 2/20 0.43
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
MCL1 Q07820 1/20 0.41
CYP3A4 P08684 1/20 0.41
PPARG P37231 1/20 0.41
LGALS8 O00214 1/20 0.41
LGALS1 P09382 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269555 0.80 MCL1 (0.46) FLT1FLT4KDRMEN1MAPT
SCHEMBL1268486 0.79 POLB (0.51) FLT1FLT4KDREDNRATSHR
SCHEMBL418863 0.78 MAPT (0.50) FLT1FLT4KDRITGA1MEN1
SCHEMBL10633357 0.75 FLT1 (0.58) FLT1FLT4KDRMEN1KMT2A
SCHEMBL8555843 0.74 CA1 (0.32) KMT2ACYP3A4PPARG
Acetic Acid SCHEMBL28282467 0.73 POLB (0.49) FLT1FLT4KDRHDAC1HDAC8
SCHEMBL11156882 0.73 CA12 (0.59) MEN1LMNAKMT2ATSHR
SCHEMBL2371055 0.73 CA12 (0.53) ITGA1MEN1LMNAMAPTALOX12
SCHEMBL2371049 0.73 MEN1 (0.49) FLT1FLT4KDRITGA1MEN1
SCHEMBL8558197 0.72 ALDH1A1 (0.31) SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 EP disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 US disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG FLT1 1549/4885FLT4 917/4885KDR 1812/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG FLT1 1549/4885FLT4 917/4885KDR 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.